Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Phase 1 summary of plasma concentration-QTc analysis for idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors and AML.

Blotner S, Chen LC, Ferlini C, Zhi J.

Cancer Chemother Pharmacol. 2018 Mar;81(3):597-607. doi: 10.1007/s00280-018-3534-7. Epub 2018 Feb 1.

PMID:
29392451
2.

Effects of posaconazole (a strong CYP3A4 inhibitor), two new tablet formulations, and food on the pharmacokinetics of idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors.

Nemunaitis J, Young A, Ejadi S, Miller W, Chen LC, Nichols G, Blotner S, Vazvaei F, Zhi J, Razak A.

Cancer Chemother Pharmacol. 2018 Mar;81(3):529-537. doi: 10.1007/s00280-018-3521-z. Epub 2018 Jan 24.

PMID:
29368050
3.

Effect of Food and Esomeprazole on the Pharmacokinetics of Alectinib, a Highly Selective ALK Inhibitor, in Healthy Subjects.

Morcos PN, Guerini E, Parrott N, Dall G, Blotner S, Bogman K, Sturm C, Balas B, Martin-Facklam M, Phipps A.

Clin Pharmacol Drug Dev. 2017 Jul;6(4):388-397. doi: 10.1002/cpdd.296. Epub 2016 Sep 28.

PMID:
27545320
4.

Acute myeloid leukemia patients' clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts.

Reis B, Jukofsky L, Chen G, Martinelli G, Zhong H, So WV, Dickinson MJ, Drummond M, Assouline S, Hashemyan M, Theron M, Blotner S, Lee JH, Kasner M, Yoon SS, Rueger R, Seiter K, Middleton SA, Kelly KR, Vey N, Yee K, Nichols G, Chen LC, Pierceall WE.

Haematologica. 2016 May;101(5):e185-8. doi: 10.3324/haematol.2015.139717. Epub 2016 Feb 11. No abstract available.

5.

Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia.

Andreeff M, Kelly KR, Yee K, Assouline S, Strair R, Popplewell L, Bowen D, Martinelli G, Drummond MW, Vyas P, Kirschbaum M, Iyer SP, Ruvolo V, González GM, Huang X, Chen G, Graves B, Blotner S, Bridge P, Jukofsky L, Middleton S, Reckner M, Rueger R, Zhi J, Nichols G, Kojima K.

Clin Cancer Res. 2016 Feb 15;22(4):868-76. doi: 10.1158/1078-0432.CCR-15-0481. Epub 2015 Oct 12.

6.

Safety, tolerability, and pharmacokinetics of ribavirin in hepatitis C virus-infected patients with various degrees of renal impairment.

Brennan BJ, Wang K, Blotner S, Magnusson MO, Wilkins JJ, Martin P, Solsky J, Nieforth K, Wat C, Grippo JF.

Antimicrob Agents Chemother. 2013 Dec;57(12):6097-105. doi: 10.1128/AAC.00608-13. Epub 2013 Sep 30.

7.

Influence of chronic hepatitis C infection on cytochrome P450 3A4 activity using midazolam as an in vivo probe substrate.

Morcos PN, Moreira SA, Brennan BJ, Blotner S, Shulman NS, Smith PF.

Eur J Clin Pharmacol. 2013 Oct;69(10):1777-84. doi: 10.1007/s00228-013-1525-5. Epub 2013 Jun 14.

PMID:
23765407
8.

Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors.

Leijen S, Middleton MR, Tresca P, Kraeber-Bodéré F, Dieras V, Scheulen ME, Gupta A, Lopez-Valverde V, Xu ZX, Rueger R, Tessier JJ, Shochat E, Blotner S, Naegelen VM, Schellens JH, Eberhardt WE.

Clin Cancer Res. 2012 Sep 1;18(17):4794-805. Epub 2012 Jul 5.

9.

First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors.

Martinez-Garcia M, Banerji U, Albanell J, Bahleda R, Dolly S, Kraeber-Bodéré F, Rojo F, Routier E, Guarin E, Xu ZX, Rueger R, Tessier JJ, Shochat E, Blotner S, Naegelen VM, Soria JC.

Clin Cancer Res. 2012 Sep 1;18(17):4806-19. Epub 2012 Jul 3.

10.

Impact of low-dose ritonavir on danoprevir pharmacokinetics: results of computer-based simulations and a clinical drug-drug interaction study.

Reddy MB, Chen Y, Haznedar JO, Fretland J, Blotner S, Smith P, Tran JQ.

Clin Pharmacokinet. 2012 Jul 1;51(7):457-65. doi: 10.2165/11599700-000000000-00000.

PMID:
22624502
11.

The pharmacokinetics of peginterferon alfa-2a and ribavirin in African American, Hispanic and Caucasian patients with chronic hepatitis C.

Brennan BJ, Morcos PN, Wang K, Blotner SD, Morrison R, Hagedorn CH, Marbury TC, Sulkowski M, Grippo JF.

Aliment Pharmacol Ther. 2012 May;35(10):1209-20. doi: 10.1111/j.1365-2036.2012.05079.x. Epub 2012 Apr 3.

12.

The safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of RO5068760, an MEK inhibitor, in healthy volunteers: assessment of target suppression.

Lee L, Niu H, Goelzer P, Rueger R, Deutsch J, Busse-Reid R, DeSchepper S, Blotner S, Barrett J, Weissgerber G, Peck R.

J Clin Pharmacol. 2010 Dec;50(12):1397-405. doi: 10.1177/0091270010361254. Epub 2010 Apr 12.

PMID:
20386016
13.

Effect of orlistat on fecal fat, fecal biliary acids, and colonic cell proliferation in obese subjects.

Ahnen DJ, Guerciolini R, Hauptman J, Blotner S, Woods CJ, Wargovich MJ.

Clin Gastroenterol Hepatol. 2007 Nov;5(11):1291-9. Epub 2007 Oct 24.

PMID:
17920338
14.

Chronic hepatitis C in patients with persistently normal alanine transaminase levels.

Shiffman ML, Diago M, Tran A, Pockros P, Reindollar R, Prati D, Rodríguez-Torres M, Lardelli P, Blotner S, Zeuzem S.

Clin Gastroenterol Hepatol. 2006 May;4(5):645-52. Erratum in: Clin Gastroenterol Hepatol. 2006 Aug;4(8):1072.

PMID:
16630770
15.

Viral and metabolic factors influencing alanine aminotransferase activity in patients with chronic hepatitis C.

Prati D, Shiffman ML, Diago M, Gane E, Rajender Reddy K, Pockros P, Farci P, O'Brien CB, Lardelli P, Blotner S, Zeuzem S.

J Hepatol. 2006 Apr;44(4):679-85. Epub 2006 Jan 25.

PMID:
16487620
16.

Short-term orlistat treatment does not affect mineral balance and bone turnover in obese men.

Pace DG, Blotner S, Guerciolini R.

J Nutr. 2001 Jun;131(6):1694-9.

PMID:
11385055
17.

Orlistat fails to alter postprandial plasma lipid excursions or plasma lipases in normal-weight male volunteers.

Shepard TY, Jensen DR, Blotner S, Zhi J, Guerciolini R, Pace D, Eckel RH.

Int J Obes Relat Metab Disord. 2000 Feb;24(2):187-94.

PMID:
10702769
19.

The effects of drug therapy on radiographic progression of rheumatoid arthritis. Results of a 36-week randomized trial comparing methotrexate and auranofin.

Weinblatt ME, Polisson R, Blotner SD, Sosman JL, Aliabadi P, Baker N, Weissman BN.

Arthritis Rheum. 1993 May;36(5):613-9. Erratum in: Arthritis Rheum 1993 Jul;36(7):1028.

PMID:
8489539

Supplemental Content

Loading ...
Support Center